Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Eribulin mesylate in Advanced Triple-Negative Breast Carcinoma: NCT07441512 Clinical Landscape Report 2026
16 September 2026
NCT07441512 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Emicizumab in Hemophilic arthropathy: NCT07439055 Clinical Landscape Report 2026
16 September 2026
NCT07439055 clinical landscape for Hemophilic arthropathy: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AFN-50 in Idiopathic Inflammatory Myopathies: NCT07448298 Clinical Landscape Report 2026
16 September 2026
NCT07448298 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
FZ-AD005 in Glioblastoma, IDH-Wildtype: NCT07455045 Clinical Landscape Report 2026
16 September 2026
NCT07455045 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KL-003 in Anemia, Sickle Cell: NCT07436767 Clinical Landscape Report 2026
16 September 2026
NCT07436767 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NM-6606 in Metabolic Dysfunction Associated Steatohepatitis: NCT07462455 Clinical Landscape Report 2026
16 September 2026
NCT07462455 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Temozolomide in Glioblastoma: NCT07457307 Clinical Landscape Report 2026
16 September 2026
NCT07457307 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT07460206 Clinical Landscape Report 2026
16 September 2026
NCT07460206 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLIX1 in Glioblastoma Multiforme: NCT07464925 Clinical Landscape Report 2026
16 September 2026
NCT07464925 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EVM-18001 in Scleroderma: NCT07470151 Clinical Landscape Report 2026
16 September 2026
NCT07470151 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BGB-58067 in Glioblastoma: NCT07485049 Clinical Landscape Report 2026
16 September 2026
NCT07485049 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech) in Triple Negative Breast Cancer: NCT07486089 Clinical Landscape Report 2026
16 September 2026
NCT07486089 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.